Results 121 to 130 of about 455 (155)

Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide

European Journal of Clinical Pharmacology, 1979
Ten patients with persistent ventricular arrhythmia were studied in a comparison of the antiarrhythmic efficacy of N-acetylprocainamide (NAPA) and procainamide (PA). Each patient performed three exercise tests for 40 min., on different days, with submaximal and fixed work loads. During the first exercise test no drug was administered.
C, Sonnhag, E, Karlsson
openaire   +2 more sources

N-Acetylprocainamide's Antiarrhythmic Action in Patients with Ventricular Tachycardia

Angiology, 1986
Antiarrhythmic properties of N-acetylprocainamide, an active metabolite of procainamide, were studied in 15 patients who presented with a cardiac arrest or documented sustained ventricular tachycardia. Programmed electrical stimulation studies were performed.
J, Somberg, J, Wynn, D, Miura, V, Torres, S, Williams, D, Keefe   +5 more
openaire   +2 more sources

Effect kinetics of N-acetylprocainamide-induced QT interval prolongation

Clinical Pharmacology and Therapeutics, 1987
We attempted to correlate clinical response with the effects of N-acetylprocainamide (NAPA) on the QT interval in five patients with stable chronic ventricular arrhythmias. A 15 mg/kg dose of NAPA was administered and a pharmacokinetic-pharmacodynamic model was used to relate plasma NAPA concentrations to changes in corrected QT interval (QTc).
A A, Piergies, T I, Ruo, E M, Jansyn, S M, Belknap, A J, Atkinson   +4 more
openaire   +2 more sources

Trimethoprim alters the disposition of procainamide and N-acetylprocainamide

Clinical Pharmacology and Therapeutics, 1988
The steady-state pharmacokinetics and pharmacodynamics of procainamide and its active N-acetyl metabolite (NAPA) were assessed alone and in combination with trimethoprim. Eight healthy men received oral sustained-release procainamide, 500 mg every 6 hours for 3 days, alone and with oral trimethoprim, 200 mg daily for 4 days.
T, Kosoglou, M L, Rocci, P H, Vlasses
openaire   +2 more sources

N-Acetylprocainamide kinetics after single and repeated oral doses

Clinical Pharmacology and Therapeutics, 1982
The kinetic behavior of N-acetylprocainamide (NAPA) was studied after single and repeated oral doses in six healthy subjects and five patients with cardiomyopathy. Renal clearance (CLR) of NAPA was lower in patients than in normal subjects after an initial 1-gm dose (1.3 +/- 0.4 [x +1- SD] and 2.7 +/- 0.4 ml . min-1 .
T M, Ludden, M H, Crawford
openaire   +2 more sources

Clinical Evaluation of the EMIT® Procainamide and N-Acetylprocainamide Assay

Therapeutic Drug Monitoring, 1979
Procainamide and its major metabolite, N-acetylprocainamide, were measured by the homogeneous enzyme immunoassay technique (EMIT). The reagents for the EMIT assays were supplied as a separate matched set for each assay. There is no cross-reactivity by procainamide in the assay for N-acetylprocainamide or by N-acetylprocainamide in the assay for ...
C B, Walberg, S H, Wan
openaire   +2 more sources

N‐acetylprocainamide levels in patients with end‐stage renal failure

Clinical Pharmacology & Therapeutics, 1976
Serum concentrations of pro cain amide (PA) and N‐acetylprocainamide (NAPA) were measured by fluorometry in subjects with normal renal function (n = 4) and in patients with end‐stage renal failure (n = 3) after administration of 6.5 mg/kg of PA · HCI orally.
T P, Gibson, E J, Matusik, W A, Briggs
openaire   +2 more sources

Acecainide (N-Acetylprocainamide)

Drugs, 1990
Acecainide (N-acetylprocainamide), the N-acetylated metabolite of procainamide, is a Class III antiarrhythmic agent. It can be given either intravenously or orally, and is eliminated primarily by renal excretion. In a small number of noncomparative and placebo-controlled short term therapeutic trials acecainide markedly reduced premature ventricular ...
D W, Harron, R N, Brogden
openaire   +2 more sources

Comparative Vagolytic Effects of Procainamide and N- Acetylprocainamide in the Dog

Journal of Cardiovascular Pharmacology, 1983
Procainamide exerts vagolytic effects which are deleterious in clinical therapy for supraventricular arrhythmias. The purpose of the present study was to determine if N-acetylprocainamide (NAPA), an active metabolite of procainamide which has been proposed as an effective and less toxic alternative, would exert an equivalent degree of vagal blockade ...
D L, Pearle, J D, Souza, R A, Gillis
openaire   +2 more sources

Kinetic Analysis of the Vasodilator and Ganglionic Blocking Actions of N-Acetylprocainamide

Journal of Cardiovascular Pharmacology, 1982
The hypotensive effects of N-acetylprocainamide (NAPA) were studied in anesthetized dogs and in a normal subject. In dogs, intravenous NAPA infusions reduced mean arterial pressure and the pressor response of the isolated, perfused gracilis muscle vascular bed to preganglionic, but not postganglionic, sympathetic stimulation.
J R, Eudeikis, T K, Henthorn, J J, Lertora, A J, Atkinson, G C, Chao, W, Kushner   +5 more
openaire   +2 more sources